Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU

Mar Riveiro Barciela; Sabela Carballal Ramil; Álvaro Díaz González; Miriam Mañosa; Javier Gallego Plazas; Joaquín Cubiella Fernández; P. Jiménez Fonseca; María Varela; Luis Alberto Menchén; Bruno Sangro Gómez Acebo; Ana Fernández Montes; Francisco Mesonero Gismero; Miguel Ángel Rodríguez Gandía; Fernando Rivera Herrero; María Carlota Londoño Hurtado

Ayuda

Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU

Mar Riveiro-Barciela ^[1] ; Sabela carballal ^[1] ; Álvaro Díaz-González ^[2] ; Miriam Mañosa ^[1] ; Javier Gallego-Plazas ^[3] ; Joaquín Cubiella ^[1] ; Paula Jiménez-Fonseca ^[4] ; María Varela ^[4] ; Luis Menchén ^[5] ; Bruno Sangro ^[1] ; Ana Fernández-Montes ^[6] ; Francisco Mesonero ^[7] ; Miguel Ángel Rodríguez-Gandía ^[7] ; Fernando Rivera ^[2] ; María-Carlota Londoño ^[1]
1. [1] Instituto de Salud Carlos III
  
  Instituto de Salud Carlos III
  
  Madrid, España
2. [2] Hospital Universitario Marqués de Valdecilla
  
  Hospital Universitario Marqués de Valdecilla
  
  Santander, España
3. [3] Hospital General Universitario de Elche
  
  Hospital General Universitario de Elche
  
  Elche, España
4. [4] Hospital Universitario Central de Asturias
  
  Hospital Universitario Central de Asturias
  
  Oviedo, España
5. [5] Instituto de Investigación Sanitaria Gregorio Marañón
  
  Instituto de Investigación Sanitaria Gregorio Marañón
  
  Madrid, España
6. [6] Complexo Hospitalario Universitario de Ourense
  
  Complexo Hospitalario Universitario de Ourense
  
  Ourense, España
7. [7] Hospital Ramón y Cajal
  
  Hospital Ramón y Cajal
  
  Madrid, España
Mostrar afiliaciones +
Localización: Revista Española de Enfermedades Digestivas, ISSN-e 2340-4167, ISSN 1130-0108, Vol. 116, Nº. 2, 2024, págs. 83-113
Idioma: inglés
Enlaces
- Texto completo
Resumen
- The development of the immune checkpoint inhibitors (ICI) is one of the most remarkable achievements in cancer therapy in recent years. However, their exponential use has led to an increase in immune-related adverse events (irAEs). Gastrointestinal and liver events encompass hepatitis, colitis and upper digestive tract symptoms accounting for the most common irAEs, with incidence rates varying from 2 % to 40 %, the latter in patients undergoing combined ICIs therapy. Based on the current scientific evidence derived from both randomized clinical trials and real-world studies, this statement document provides recommendations on the diagnosis, treatment and prognosis of the gastrointestinal and hepatic ICI-induced adverse events.